Small Esperion Vs. Pharma Giants In The Cholesterol Race
There are 3 articles on this stock available only to PRO subscribers.
Tue, Aug. 12, 8:18 AM
Tue, Aug. 12, 7:38 AM
- Esperion Therapeutics (NASDAQ:ESPR) Q2 results: Revenues: $0; Net Loss: ($9.2M) (-33.5%); Loss Per Share: ($0.60) (+97.0%); Quick Assets: $47.9M (-15.2%).
- 2014 Guidance: Cash burn: $37M - 40M; quick assets at year end should be approximately $42M - 45M and should be sufficient to fund operations into early 2016.
Mon, May. 12, 5:31 PM
Wed, Mar. 5, 6:02 PM
Aug. 12, 2013, 8:31 AM
ESPR vs. ETF Alternatives
Other News & PR